MARKET

OKUR

OKUR

OnKure Therapeutics
NASDAQ
1.830
-0.010
-0.54%
After Hours: 1.830 0 0.00% 16:05 05/14 EDT
OPEN
1.850
PREV CLOSE
1.840
HIGH
1.970
LOW
1.770
VOLUME
81.95K
TURNOVER
--
52 WEEK HIGH
20.00
52 WEEK LOW
1.700
MARKET CAP
24.72M
P/E (TTM)
-0.1380
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OKUR last week (0505-0509)?
Weekly Report · 2d ago
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
TipRanks · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Cigna (CI)
TipRanks · 05/07 08:20
OnKure Therapeutics Reports Q1 2025 Progress and Financials
TipRanks · 05/07 04:39
Oppenheimer Keeps Their Buy Rating on OnKure Therapeutics (OKUR)
TipRanks · 05/06 20:35
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), OnKure Therapeutics (OKUR) and Neuronetics (STIM)
TipRanks · 05/06 19:30
OnKure Therapeutics GAAP EPS of $1.19
Seeking Alpha · 05/06 15:40
OnKure Therapeutics Q1 EPS $(1.19) Beats $(1.46) Estimate
Benzinga · 05/06 11:47
More
About OKUR
More
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Recently
Symbol
Price
%Change

Webull offers Onkure Therapeutics Inc stock information, including NASDAQ: OKUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKUR stock methods without spending real money on the virtual paper trading platform.